The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 12,168.00
Ask: 12,170.00
Change: -74.00 (-0.60%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-UK detects S.African coronavirus variant in people with no travel links

Mon, 01st Feb 2021 12:28

(Adds government statement, details)

LONDON, Feb 1 (Reuters) - Eleven people in different regions
have tested positive for the South African coronavirus variant
without having any links to people who have travelled recently,
prompting mass testing in the areas to contain the outbreak.

The government said on Monday the cases were now
self-isolating and robust contact tracing had taken place to
trace their contacts and ask them to self-isolate.

Residents in eight postcodes - three in London; two in the
south east and one in the West Midlands, east of England, and
the North West - would now be tested for the new coronavirus
whether they are showing any symptoms or not under what is known
as "surge testing" it said.

"Every person over 16 living in these locations is strongly
encouraged to take a Covid test this week, whether they are
showing symptoms or not," the government said in a statement.

The government said in January it had detected cases of both
the South African and Brazilian variants, but all were linked to
travel.

In total, Public Health England said it had identified 105
cases of the South African variant since Dec 22.

All viruses mutate frequently, and scientists have
identified several variants of the novel coronavirus found to be
more transmissible than the original strain.

The emergence of more infectious variants has raised
questions over whether vaccines will prove as effective in
containing them.

Scientists have said the South African variant appears to be
more transmissible, but there is no evidence it causes more
severe disease. But several laboratory studies have found that
it reduces vaccine and antibody therapy efficacy.

Clinical trial data on two COVID-19 vaccines - from Novavax
and Johnson & Johnson - released on Saturday showed they had
less ability to protect against the illness caused by the South
African variant.

But the Surrey Local Resilience Forum said there was no
evidence the regulated vaccine would not protect against it. The
Oxford-AstraZeneca and Pfizer-BioNTech vaccines are being rolled
out across Britain.

(Reporting by Kate Holton, Michael Holden and Paul Sandle,
editing by Estelle Shirbon and Timothy Heritage)

More News
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more
30 Oct 2023 09:40

LONDON BROKER RATINGS: Jefferies cuts NatWest to underperform from buy

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.